Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
21
07
2022
pubmed:
13
8
2022
medline:
27
8
2022
entrez:
12
8
2022
Statut:
ppublish
Résumé
Peripheral artery disease (PAD) is the occlusion or narrowing of the arteries supplying the lower extremities. Peripheral artery disease has been estimated to affect approximately 240 million people worldwide, approximately 70% of whom are within low- or middle-income countries. Due to the ageing population and diabetes epidemic, the prevalence of PAD is rapidly rising. The symptoms of PAD are heterogeneous and thus a high index of suspicion is needed to prevent delays in diagnosis and treatment. Measurement of ankle brachial pressure index or arterial duplex ultrasound are traditionally used to diagnose PAD. Patients with PAD have a high risk of major adverse cardiovascular events. Early diagnosis and implementation of secondary cardiovascular prevention is therefore critical. This includes therapies to reduce low-density lipoprotein cholesterol, such as statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, blood-pressure reducing medications and anti-thrombotic drugs. Treatments to facilitate smoking cessation and control blood sugar if relevant and an exercise programme are also critical in reducing cardiovascular risk. Currently, these treatments are not well implemented. This review summarises the clinical presentation, risk factors and medical management of PAD. Global efforts are needed to reduce the burden from the growing PAD epidemic by implementing best practices and improving outcomes through further research.
Identifiants
pubmed: 35960432
doi: 10.1007/s40265-022-01755-7
pii: 10.1007/s40265-022-01755-7
doi:
Substances chimiques
Cholesterol, LDL
0
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Ezetimibe
EOR26LQQ24
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165-1177Subventions
Organisme : National Institute for Health Care Management Foundation
ID : R01DK124789
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. Nat Rev Cardiol. 2022;19(7):456–74.
pubmed: 34997200
doi: 10.1038/s41569-021-00663-9
Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020–30.
pubmed: 31303293
doi: 10.1016/S2214-109X(19)30255-4
Bjorck M, Earnshaw JJ, Acosta S, Bastos Goncalves F, Cochennec F, Debus ES, et al. Editor’s Choice-European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia. Eur J Vasc Endovasc Surg. 2020;59(2):173–218.
pubmed: 31899099
doi: 10.1016/j.ejvs.2019.09.006
Golledge J, Leicht AS, Yip L, Rowbotham SE, Pinchbeck J, Jenkins JS, et al. Relationship between disease specific quality of life measures, physical performance, and activity in people with intermittent claudication caused by peripheral artery disease. Eur J Vasc Endovasc Surg. 2020;59(6):957–64.
pubmed: 32336621
doi: 10.1016/j.ejvs.2020.02.006
Golledge J, Pinchbeck J, Rowbotham SE, Yip L, Jenkins JS, Quigley F, et al. Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate. Sci Rep. 2020;10(1):14583.
pubmed: 32884020
pmcid: 7471934
doi: 10.1038/s41598-020-71454-4
Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517–38.
pubmed: 9308598
doi: 10.1016/S0741-5214(97)70045-4
Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1):S1–109.
pubmed: 31182334
pmcid: 8369495
doi: 10.1016/j.ejvs.2019.05.006
Golledge J, Drovandi A. Evidence-based recommendations for medical management of peripheral artery disease. J Atheroscler Thromb. 2021;28(6):573–83.
pubmed: 33746159
pmcid: 8219542
doi: 10.5551/jat.62778
Saxon JT, Safley DM, Mena-Hurtado C, Heyligers J, Fitridge R, Shishehbor M, et al. Adherence to guideline-recommended therapy-including supervised exercise therapy referral-across peripheral artery disease specialty clinics: insights from the International PORTRAIT Registry. J Am Heart Assoc. 2020;9(3): e012541.
pubmed: 31973609
pmcid: 7033887
doi: 10.1161/JAHA.119.012541
Newman AB. Peripheral arterial disease: insights from population studies of older adults. J Am Geriatr Soc. 2000;48(9):1157–62.
pubmed: 10983919
doi: 10.1111/j.1532-5415.2000.tb04795.x
Schorr EN, Treat-Jacobson D. Methods of symptom evaluation and their impact on peripheral artery disease (PAD) symptom prevalence: a review. Vasc Med. 2013;18(2):95–111.
pubmed: 23509087
pmcid: 3654822
doi: 10.1177/1358863X13480001
Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45(10):1101–9.
pubmed: 1474406
doi: 10.1016/0895-4356(92)90150-L
Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–24.
pubmed: 11560536
doi: 10.1001/jama.286.11.1317
McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian L, Liao Y, et al. Leg symptom categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr Soc. 2010;58(7):1256–62.
pubmed: 20550604
pmcid: 3227868
doi: 10.1111/j.1532-5415.2010.02941.x
Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, Rogers K, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014;60(3):686-95 e2.
pubmed: 24820900
doi: 10.1016/j.jvs.2014.03.290
Misra S, Shishehbor MH, Takahashi EA, Aronow HD, Brewster LP, Bunte MC, et al. Perfusion assessment in critical limb ischemia: principles for understanding and the development of evidence and evaluation of devices: a scientific statement from the American Heart Association. Circulation. 2019;140(12):e657–72.
pubmed: 31401843
pmcid: 7372288
doi: 10.1161/CIR.0000000000000708
Abola MTB, Golledge J, Miyata T, Rha SW, Yan BP, Dy TC, et al. Asia-Pacific Consensus Statement on the management of peripheral artery disease: a report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. J Atheroscler Thromb. 2020;27(8):809–907.
pubmed: 32624554
pmcid: 7458790
doi: 10.5551/jat.53660
Golledge J, Moxon JV, Rowbotham S, Pinchbeck J, Quigley F, Jenkins J. High ankle brachial index predicts high risk of cardiovascular events amongst people with peripheral artery disease. PLoS ONE. 2020;15(11): e0242228.
pubmed: 33180875
pmcid: 7660483
doi: 10.1371/journal.pone.0242228
Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nat Med. 2019;25(8):1274–9.
pubmed: 31285632
pmcid: 6768096
doi: 10.1038/s41591-019-0492-5
Thomas Manapurathe D, Moxon JV, Krishna SM, Rowbotham S, Quigley F, Jenkins J, et al. Cohort study examining the association between blood pressure and cardiovascular events in patients with peripheral artery disease. J Am Heart Assoc. 2019;8(6): e010748.
pubmed: 30845872
pmcid: 6475052
doi: 10.1161/JAHA.118.010748
Nastasi DR, Moxon JV, Norman R, Trollope AF, Rowbotham S, Quigley F, et al. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease. J Vasc Surg. 2021;73(4):1396-403 e3.
pubmed: 32891803
doi: 10.1016/j.jvs.2020.08.129
Houghton JS, Nickinson AT, Helm JR, Dimitrova J, Dubkova S, Rayt HS, et al. Associations of clinical frailty with severity of limb threat and outcomes in chronic limb-threatening ischaemia. Ann Vasc Surg. 2021;76:406–16.
pubmed: 33951523
doi: 10.1016/j.avsg.2021.04.017
de II L, Hoeks SE, van Gestel YR, Klein J, Bax JJ, Verhagen HJ, et al. The prognostic value of impaired walking distance on long-term outcome in patients with known or suspected peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(4):482–7.
doi: 10.1016/j.ejvs.2009.02.022
Nayak P, Guralnik JM, Polonsky TS, Kibbe MR, Tian L, Zhao L, et al. Association of six-minute walk distance with subsequent lower extremity events in peripheral artery disease. Vasc Med. 2020;25(4):319–27.
pubmed: 32338582
doi: 10.1177/1358863X20901599
Morris DR, Rodriguez AJ, Moxon JV, Cunningham MA, McDermott MM, Myers J, et al. Association of lower extremity performance with cardiovascular and all-cause mortality in patients with peripheral artery disease: a systematic review and meta-analysis. J Am Heart Assoc. 2014;3(4):e001105.
pubmed: 25122666
pmcid: 4310407
doi: 10.1161/JAHA.114.001105
Morris DR, Skalina TA, Singh TP, Moxon JV, Golledge J. Association of computed tomographic leg muscle characteristics with lower limb and cardiovascular events in patients with peripheral artery disease. J Am Heart Assoc. 2018;7(20): e009943.
pubmed: 30371256
pmcid: 6474956
doi: 10.1161/JAHA.118.009943
McDermott MM, Ferrucci L, Gonzalez-Freire M, Kosmac K, Leeuwenburgh C, Peterson CA, et al. Skeletal muscle pathology in peripheral artery disease: a brief review. Arterioscler Thromb Vasc Biol. 2020;40(11):2577–85.
pubmed: 32938218
doi: 10.1161/ATVBAHA.120.313831
McDermott MM, Guralnik JM, Tian L, Liu K, Ferrucci L, Liao Y, et al. Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation study). J Am Coll Cardiol. 2009;53(12):1056–62.
pubmed: 19298919
pmcid: 3215766
doi: 10.1016/j.jacc.2008.09.063
Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, et al. Optimal exercise programs for patients with peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139(4):e10–33.
pubmed: 30586765
doi: 10.1161/CIR.0000000000000623
Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, et al. Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: a science advisory from the American Heart Association. Circulation. 2019;140(13):e700–10.
pubmed: 31446770
doi: 10.1161/CIR.0000000000000727
Golledge J, Singh TP, Alahakoon C, Pinchbeck J, Yip L, Moxon JV, et al. Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease. Br J Surg. 2019;106(4):319–31.
pubmed: 30791089
doi: 10.1002/bjs.11101
Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017;12:CD000990.
pubmed: 29278423
Harwood AE, Smith GE, Cayton T, Broadbent E, Chetter IC. A systematic review of the uptake and adherence rates to supervised exercise programs in patients with intermittent claudication. Ann Vasc Surg. 2016;34:280–9.
pubmed: 27126713
doi: 10.1016/j.avsg.2016.02.009
Hageman SHJ, de Borst GJ, Dorresteijn JAN, Bots ML, Westerink J, Asselbergs FW, et al. Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. Heart. 2020;106(21):1686–92.
pubmed: 32170038
doi: 10.1136/heartjnl-2019-316088
Golledge J, Velu R, Quigley F, Jenkins J, Singh TP. Cohort study examining the prevalence and relationship with outcome of standard modifiable risk factors in patients with peripheral artery occlusive and aneurysmal disease. Eur J Vasc Endovasc Surg. 2022;63(2):305–13.
pubmed: 34916106
doi: 10.1016/j.ejvs.2021.10.039
Thanigaimani S, Drovandi A, Golledge J. A meta-analysis of randomized controlled trials evaluating the efficacy of smoking cessation interventions in people with peripheral artery disease. J Vasc Surg. 2022;75(2):721-9 e7.
pubmed: 34600029
doi: 10.1016/j.jvs.2021.07.248
Hennrikus D, Joseph AM, Lando HA, Duval S, Ukestad L, Kodl M, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol. 2010;56(25):2105–12.
pubmed: 21144971
doi: 10.1016/j.jacc.2010.07.031
Heart Protection Study Collaborative G. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645–54 (discussion 53–4).
doi: 10.1016/j.jvs.2006.12.054
Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17–24.
pubmed: 14683738
doi: 10.1016/j.ehj.2003.10.033
Group. TSR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.
doi: 10.1056/NEJMoa1511939
Frary J, Byrne C, Vaduganathan M, Biering-srensen T, Olsen MH, Bhatt DL, et al. Abstract 13760: intensive versus standard blood pressure control in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial (SPRINT). Circulation. 2020;142(Suppl_3):A13760-A.
doi: 10.1161/circ.142.suppl_3.13760
ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.
doi: 10.1056/NEJMoa1001286
West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011;218(1):156–62.
pubmed: 21570685
pmcid: 3157540
doi: 10.1016/j.atherosclerosis.2011.04.005
Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934–43.
pubmed: 30396865
doi: 10.1016/S2213-8587(18)30290-0
Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, et al. Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. J Am Coll Cardiol. 2018;72(25):3274–84.
pubmed: 30573030
doi: 10.1016/j.jacc.2018.09.078
Fernando ME, Seneviratne RM, Tan YM, Lazzarini PA, Sangla KS, Cunningham M, et al. Intensive versus conventional glycaemic control for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2016;2016(1):CD010764.
pmcid: 8627701
Goldman MP, Clark CJ, Craven TE, Davis RP, Williams TK, Velazquez-Ramirez G, et al. Effect of intensive glycemic control on risk of lower extremity amputation. J Am Coll Surg. 2018;227(6):596–604.
pubmed: 30336205
doi: 10.1016/j.jamcollsurg.2018.09.021
Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev. 2011;11(11):CD001272.
Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS ONE. 2015;10(8): e0135692.
pubmed: 26274912
pmcid: 4537264
doi: 10.1371/journal.pone.0135692
Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–19.
pubmed: 19436018
doi: 10.1001/jama.2009.623
Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
pmcid: 64503
doi: 10.1136/bmj.324.7329.71
Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261(3):276–84.
pubmed: 17305650
doi: 10.1111/j.1365-2796.2006.01763.x
Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–39.
doi: 10.1016/S0140-6736(96)09457-3
Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO trial. Eur J Prev Cardiol. 2015;22(6):734–42.
pubmed: 24830710
doi: 10.1177/2047487314533215
Hiatt WR, Fowkes FGR, Heizer G, Berger JS, Baumgartner I, Held P, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2016;376(1):32–40.
pubmed: 27959717
doi: 10.1056/NEJMoa1611688
Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. Editor’s choice—2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305–68.
pubmed: 28851596
doi: 10.1016/j.ejvs.2017.07.018
Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(12):e726–79.
pubmed: 27840333
Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338–50.
pubmed: 29133605
doi: 10.1161/CIRCULATIONAHA.117.032235
Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular disease: reappraisal of the current clinical landscape. Circ Cardiovasc Interv. 2019;12(12): e007385.
pubmed: 31833412
pmcid: 7660526
doi: 10.1161/CIRCINTERVENTIONS.119.007385
Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation. 2021;144(9):e171–91.
pubmed: 34315230
doi: 10.1161/CIR.0000000000001005
Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–6.
pubmed: 1729621
doi: 10.1056/NEJM199202063260605
Yazdani B, Kleber ME, Yücel G, Delgado GE, Husain-Syed F, Krüger B, et al. Polyvascular disease, pulse pressure and mortality. Vasa. 2022;51(4):229–38.
pubmed: 35603601
doi: 10.1024/0301-1526/a001011
Weissler EH, Jones WS, Desormais I, Debus S, Mazzolai L, Espinola-Klein C, et al. Polyvascular disease: a narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. 2020;315:10–7.
pubmed: 33190107
doi: 10.1016/j.atherosclerosis.2020.11.001
Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol. 2021;6(1):21–9.
pubmed: 32997098
Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, et al. Total cardiovascular and limb events and the impact of polyvascular disease in chronic symptomatic peripheral artery disease. J Am Heart Assoc. 2022;11(11): e025504.
pubmed: 35621222
pmcid: 9238734
doi: 10.1161/JAHA.122.025504
Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74(9):1167–76.
pubmed: 30898609
doi: 10.1016/j.jacc.2019.03.013
Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–29.
pubmed: 29132880
doi: 10.1016/S0140-6736(17)32409-1
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004.
pubmed: 32222135
doi: 10.1056/NEJMoa2000052
Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, et al. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022;29(5):e181–e189.
pubmed: 34463737
doi: 10.1093/eurjpc/zwab128
Anand SS, Eikelboom JW, Dyal L, Bosch J, Neumann C, Widimsky P, et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial. J Am Coll Cardiol. 2019;73(25):3271–80.
pubmed: 31248548
doi: 10.1016/j.jacc.2019.02.079
Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation. 2018;137(4):405–7.
pubmed: 29133602
doi: 10.1161/CIRCULATIONAHA.117.032031
Arnott C, Huang Y, Neuen BL, Di Tanna GL, Cannon CP, Oh R, et al. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes Metab. 2020;22(10):1753–66.
pubmed: 32436638
doi: 10.1111/dom.14091
Thanigaimani S, Phie J, Sharma C, Wong S, Ibrahim M, Huynh P, et al. Network meta-analysis comparing the outcomes of treatments for intermittent claudication tested in randomized controlled trials. J Am Heart Assoc. 2021;10(9): e019672.
pubmed: 33890475
pmcid: 8200724
doi: 10.1161/JAHA.120.019672
Jansen SCP, van Nistelrooij LPJ, Scheltinga MRM, Rouwet EV, Teijink JAW, Vahl AC. Successful implementation of the exercise first approach for intermittent claudication in The Netherlands is associated with few lower limb revascularisations. Eur J Vasc Endovasc Surg. 2020;60(6):881–7.
pubmed: 32888779
doi: 10.1016/j.ejvs.2020.07.074
McDermott MM, Spring B, Tian L, Treat-Jacobson D, Ferrucci L, Lloyd-Jones D, et al. Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial. JAMA. 2021;325(13):1266–76.
pubmed: 33821898
pmcid: 8025122
doi: 10.1001/jama.2021.2536
Brown T, Forster RB, Cleanthis M, Mikhailidis DP, Stansby G, Stewart M. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2021;6:CD003748.
pubmed: 34192807
Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, et al. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf. 2017;26(6):615–24.
pubmed: 28133890
pmcid: 5484386
doi: 10.1002/pds.4167
Verwer MC, Wijnand JGJ, Teraa M, Verhaar MC, de Borst GJ. Long term survival and limb salvage in patients with non-revascularisable chronic limb threatening ischaemia. Eur J Vasc Endovasc Surg. 2021;62(2):225–32.
pubmed: 34090781
doi: 10.1016/j.ejvs.2021.04.003